You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

RESTORIL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Restoril patents expire, and when can generic versions of Restoril launch?

Restoril is a drug marketed by Specgx Llc and is included in one NDA.

The generic ingredient in RESTORIL is temazepam. There are seven drug master file entries for this compound. Twenty-seven suppliers are listed for this compound. Additional details are available on the temazepam profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Restoril

A generic version of RESTORIL was approved as temazepam by NOVEL LABS INC on April 21st, 1987.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for RESTORIL?
  • What are the global sales for RESTORIL?
  • What is Average Wholesale Price for RESTORIL?
Summary for RESTORIL
Drug patent expirations by year for RESTORIL
Drug Prices for RESTORIL

See drug prices for RESTORIL

Recent Clinical Trials for RESTORIL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Massachusetts General HospitalN/A
State University of New York - Upstate Medical UniversityPhase 2

See all RESTORIL clinical trials

Pharmacology for RESTORIL
Drug ClassBenzodiazepine
Paragraph IV (Patent) Challenges for RESTORIL
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
RESTORIL Capsules temazepam 7.5 mg 018163 1 2006-11-01

US Patents and Regulatory Information for RESTORIL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Specgx Llc RESTORIL temazepam CAPSULE;ORAL 018163-003 Oct 25, 1991 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Specgx Llc RESTORIL temazepam CAPSULE;ORAL 018163-002 Approved Prior to Jan 1, 1982 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Specgx Llc RESTORIL temazepam CAPSULE;ORAL 018163-001 Approved Prior to Jan 1, 1982 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Specgx Llc RESTORIL temazepam CAPSULE;ORAL 018163-004 Nov 2, 2004 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for RESTORIL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Specgx Llc RESTORIL temazepam CAPSULE;ORAL 018163-003 Oct 25, 1991 ⤷  Sign Up ⤷  Sign Up
Specgx Llc RESTORIL temazepam CAPSULE;ORAL 018163-003 Oct 25, 1991 ⤷  Sign Up ⤷  Sign Up
Specgx Llc RESTORIL temazepam CAPSULE;ORAL 018163-003 Oct 25, 1991 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for RESTORIL

See the table below for patents covering RESTORIL around the world.

Country Patent Number Title Estimated Expiration
Japan S63101325 PHARMACOLOGICAL COMPOSITION CONTAINING BENZODIAZEPINE DERIVATIVE ⤷  Sign Up
Germany 3731840 ⤷  Sign Up
Italy 1221509 COMPOSIZIONE FARMACEUTICA CONTENENTE UN DERIVATO BENZODIAZEPINICO ⤷  Sign Up
Canada 1302886 COMPOSITION PHARMACEUTIQUE CONTENANT UN DERIVE DE LA BENZODIAZEPINE (PHARMACEUTICAL COMPOSITION CONTAINING A BENZODIAZEPIN DERIVATIVE) ⤷  Sign Up
Italy 8748408 ⤷  Sign Up
Switzerland 673947 ⤷  Sign Up
Belgium 1000318 NOUVELLES COMPOSITIONS PHARMACEUTIQUES A BASE D'UN DERIVE DE LA BENZODIAZEPINE. ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.